Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11197621 | 0.76 | CDK1 (0.37) | HTTSMN1; SMN2CYP1A2L3MBTL1MAPK1 | |
| SCHEMBL2487338 | 0.75 | CDK1 (0.39) | HTTSMN1; SMN2POLBMAPK1HSD17B10 | |
| SCHEMBL11184649 | 0.74 | CDK1 (0.36) | HTTSMN1; SMN2CYP1A2L3MBTL1POLB | |
| SCHEMBL11188636 | 0.74 | CDK1 (0.36) | HTTSMN1; SMN2CYP1A2L3MBTL1POLB | |
| SCHEMBL11183310 | 0.74 | HTT (0.35) | HTTSMN1; SMN2CYP1A2L3MBTL1 | |
| Methacrylic Acid SCHEMBL12004216 | 0.69 | HTT (0.38) | HTTSMN1; SMN2CYP1A2L3MBTL1POLB | |
| SCHEMBL2360555 | 0.69 | THRB (0.53) | HTTSMN1; SMN2CYP1A2L3MBTL1POLB | |
| SCHEMBL4453201 | 0.68 | RXRA (0.45) | L3MBTL1 | |
| SCHEMBL662434 | 0.68 | BTN3A1 (0.43) | BTN3A1MAPK1HSD17B10EPHX1 | |
| SCHEMBL1835409 | 0.67 | KCNA3 (0.54) | SMN1; SMN2CYP1A2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102663-B2 | Method for producing epoxy compound having cyanuric acid skeleton | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-08-11 | — | — | US | disclosed |
| US-20130172525-A1 | METHOD FOR PRODUCING EPOXY COMPOUND HAVING CYANURIC ACID SKELETON | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-07-04 | — | — | US | disclosed |
| EP-2602256-A1 | METHOD FOR PRODUCING EPOXY COMPOUND HAVING CYANURIC ACID SKELETON | Nissan Chemical Industries, Ltd. (JP) | 2013-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172525-A1 | METHOD FOR PRODUCING EPOXY COMPOUND HAVING CYANURIC ACID SKELETON | C9, EPX, C5 | BTN3A1 2460/4885HTT 2194/4885SMN1; SMN2 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.